202 related articles for article (PubMed ID: 27482723)
21. Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
Bartolozzi A; Cirillo PF; Berry AK; Hickey ER; Thomson DS; Wu L; Zindell R; Albrecht C; Ceci A; Gemkow MJ; Nagaraja NV; Romig H; Sauer A; Riether D
Bioorg Med Chem Lett; 2015 Feb; 25(3):587-92. PubMed ID: 25575658
[TBL] [Abstract][Full Text] [Related]
22. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain.
Mitrirattanakul S; Ramakul N; Guerrero AV; Matsuka Y; Ono T; Iwase H; Mackie K; Faull KF; Spigelman I
Pain; 2006 Dec; 126(1-3):102-14. PubMed ID: 16844297
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain management.
Nelson DW; Frost JM; Tietje KR; Florjancic AS; Ryther K; Carroll WA; Dart MJ; Daza AV; Hooker BA; Grayson GK; Fan Y; Garrison TR; El-Kouhen OF; Yao B; Pai M; Chandran P; Zhu C; Hsieh GC; Meyer MD
Bioorg Med Chem Lett; 2012 Apr; 22(7):2604-8. PubMed ID: 22370265
[TBL] [Abstract][Full Text] [Related]
24. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
25. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
26. Antiallodynic Effects of Cannabinoid Receptor 2 (CB
Sheng WS; Chauhan P; Hu S; Prasad S; Lokensgard JR
Pain Res Manag; 2019; 2019():1260353. PubMed ID: 31354896
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
LaBuda CJ; Koblish M; Little PJ
Eur J Pharmacol; 2005 Dec; 527(1-3):172-4. PubMed ID: 16316653
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid 1 receptor knockout mice display cold allodynia, but enhanced recovery from spared-nerve injury-induced mechanical hypersensitivity.
Sideris A; Piskoun B; Russo L; Norcini M; Blanck T; Recio-Pinto E
Mol Pain; 2016; 12():. PubMed ID: 27206660
[TBL] [Abstract][Full Text] [Related]
29. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
30. The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.
Klauke AL; Racz I; Pradier B; Markert A; Zimmer AM; Gertsch J; Zimmer A
Eur Neuropsychopharmacol; 2014 Apr; 24(4):608-20. PubMed ID: 24210682
[TBL] [Abstract][Full Text] [Related]
31. Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
Debenham JS; Madsen-Duggan CB; Wang J; Tong X; Lao J; Fong TM; Schaeffer MT; Xiao JC; Huang CC; Shen CP; Sloan Stribling D; Shearman LP; Strack AM; Euan Macintyre D; Hale JJ; Walsh TF
Bioorg Med Chem Lett; 2009 May; 19(9):2591-4. PubMed ID: 19328684
[TBL] [Abstract][Full Text] [Related]
32. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
34. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
35. Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.
Grim TW; Morales AJ; Gonek MM; Wiley JL; Thomas BF; Endres GW; Sim-Selley LJ; Selley DE; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2016 Nov; 359(2):329-339. PubMed ID: 27535976
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
37. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
[TBL] [Abstract][Full Text] [Related]
38. Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.
Plowright AT; Nilsson K; Antonsson M; Amin K; Broddefalk J; Jensen J; Lehmann A; Jin S; St-Onge S; Tomaszewski MJ; Tremblay M; Walpole C; Wei Z; Yang H; Ulander J
J Med Chem; 2013 Jan; 56(1):220-40. PubMed ID: 23227781
[TBL] [Abstract][Full Text] [Related]
39. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.
Govaerts SJ; Hermans E; Lambert DM
Eur J Pharm Sci; 2004 Nov; 23(3):233-43. PubMed ID: 15489124
[TBL] [Abstract][Full Text] [Related]
40. Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors.
Shinoda K; Hruby VJ; Porreca F
Neurosci Lett; 2007 Jan; 411(2):143-6. PubMed ID: 17110034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
